BR112014010291A2 - composições de lipossoma combinacionais para terapia de câncer - Google Patents

composições de lipossoma combinacionais para terapia de câncer

Info

Publication number
BR112014010291A2
BR112014010291A2 BR112014010291A BR112014010291A BR112014010291A2 BR 112014010291 A2 BR112014010291 A2 BR 112014010291A2 BR 112014010291 A BR112014010291 A BR 112014010291A BR 112014010291 A BR112014010291 A BR 112014010291A BR 112014010291 A2 BR112014010291 A2 BR 112014010291A2
Authority
BR
Brazil
Prior art keywords
liposome
cancer therapy
combinatorial
liposome compositions
therapeutic
Prior art date
Application number
BR112014010291A
Other languages
English (en)
Portuguese (pt)
Inventor
J Herman Cliff
Yang Jun
H Wu Stephen
Original Assignee
Mallinckrodt Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mallinckrodt Llc filed Critical Mallinckrodt Llc
Publication of BR112014010291A2 publication Critical patent/BR112014010291A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1273—Polymersomes; Liposomes with polymerisable or polymerised bilayer-forming substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dispersion Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR112014010291A 2011-10-31 2012-10-31 composições de lipossoma combinacionais para terapia de câncer BR112014010291A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161553786P 2011-10-31 2011-10-31
PCT/US2012/062635 WO2013066903A1 (en) 2011-10-31 2012-10-31 Combinational liposome compositions for cancer therapy

Publications (1)

Publication Number Publication Date
BR112014010291A2 true BR112014010291A2 (pt) 2017-04-18

Family

ID=47146747

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014010291A BR112014010291A2 (pt) 2011-10-31 2012-10-31 composições de lipossoma combinacionais para terapia de câncer

Country Status (12)

Country Link
US (4) US9370489B2 (enExample)
EP (2) EP3424564A1 (enExample)
JP (4) JP6143767B2 (enExample)
KR (1) KR20140097215A (enExample)
CN (1) CN104023793B (enExample)
BR (1) BR112014010291A2 (enExample)
CA (1) CA2852564A1 (enExample)
ES (1) ES2694154T3 (enExample)
IL (2) IL232344B (enExample)
MX (1) MX360391B (enExample)
RU (1) RU2640934C2 (enExample)
WO (1) WO2013066903A1 (enExample)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2768444A1 (en) * 2009-07-17 2011-01-20 Rigshospitalet Loading technique for preparing radionuclide and ionophore containing liposomes in which the ionophore is 2-hydroxyquionoline (carbostyril) or structurally related 2-hydroxyquinolines
CA2807552A1 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
EP2857499A1 (en) 2010-10-01 2015-04-08 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
CA2831613A1 (en) 2011-03-31 2012-10-04 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
PT3682905T (pt) 2011-10-03 2022-04-07 Modernatx Inc Nucleósidos, nucleótidos e ácidos nucleicos modificados e respetivas utilizações
ES2923757T3 (es) 2011-12-16 2022-09-30 Modernatx Inc Composiciones de ARNm modificado
WO2013151664A1 (en) 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of proteins
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US10501512B2 (en) 2012-04-02 2019-12-10 Modernatx, Inc. Modified polynucleotides
PT2922554T (pt) 2012-11-26 2022-06-28 Modernatx Inc Arn modificado nas porções terminais
ES2967701T3 (es) * 2013-03-15 2024-05-03 Translate Bio Inc Mejora sinergística de la entrega de ácidos nucleicos mediante formulaciones mezcladas
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
JP2014227338A (ja) * 2013-05-17 2014-12-08 キヤノン株式会社 インドシアニングリーン含有粒子およびその製造方法
AU2014293013A1 (en) 2013-07-26 2016-03-17 Race Oncology Ltd. Combinatorial methods to improve the therapeutic benefit of bisantrene
US10023626B2 (en) 2013-09-30 2018-07-17 Modernatx, Inc. Polynucleotides encoding immune modulating polypeptides
KR20160067219A (ko) 2013-10-03 2016-06-13 모더나 세라퓨틱스, 인코포레이티드 저밀도 지단백질 수용체를 암호화하는 폴리뉴클레오타이드
DK3138555T3 (da) 2014-04-30 2020-12-14 Fujifilm Corp Liposomsammensætning og fremgangsmåde til fremstilling heraf
WO2016131006A1 (en) * 2015-02-13 2016-08-18 Orient Pharma Inc. Compositions and methods of tumor treatment utilizing nanoparticles
WO2016141167A1 (en) 2015-03-03 2016-09-09 Cureport, Inc. Combination liposomal pharmaceutical formulations
CA2977397A1 (en) 2015-03-03 2016-09-09 Cureport, Inc. Dual loaded liposomal pharmaceutical formulations
JP2018510859A (ja) * 2015-03-17 2018-04-19 レオン−ナノドラッグズ ゲーエムベーハー 安定化されたボロン酸化合物を含むナノ粒子
WO2016161428A1 (en) * 2015-04-02 2016-10-06 The Research Foundation For The State University Of New York Serum-stable compositions and methods for light-triggered release of materials
HRP20220156T1 (hr) 2015-09-17 2022-04-15 Modernatx, Inc. Spojevi i pripravci za unutarstaničnu isporuku terapeutskih sredstava
JP6602886B2 (ja) * 2015-11-02 2019-11-06 富士フイルム株式会社 ゲムシタビンリポソーム組成物を含む腫瘍治療剤およびキット
EP3377043A4 (en) * 2015-11-20 2019-06-26 The Regents of The University of California DEVICABLE NANOSCAL CARRIER (DNVS) FOR ADMINISTRATION THROUGH THE BLOOD-BRAIN-BARRIER, MICE AND SKIN
DK3386484T3 (da) 2015-12-10 2022-07-04 Modernatx Inc Sammensætninger og fremgangsmåder til afgivelse af terapeutiske midler
US20200282101A1 (en) * 2015-12-18 2020-09-10 Medigear International Corporation Biodegradable tumor sealant
RS63051B1 (sr) 2015-12-22 2022-04-29 Modernatx Inc Jedinjenja i kompozicije za intracelularnu isporuku agenasa
KR101630397B1 (ko) * 2015-12-31 2016-06-24 한국과학기술원 항암제-인도시아닌 그린-리포좀 복합체를 포함하는 암 치료용 조성물
WO2017142876A1 (en) 2016-02-15 2017-08-24 University Of Georgia Research Foundation, Inc. lPA-3-LOADED LIPOSOMES AND METHODS OF USE THEREOF
KR102483033B1 (ko) 2016-05-16 2022-12-30 액세스 투 어드밴스드 헬스 인스티튜트 페길화된 리포솜 및 이의 용도
EP3538067A1 (en) 2016-11-08 2019-09-18 Modernatx, Inc. Stabilized formulations of lipid nanoparticles
CN106474057A (zh) * 2016-12-02 2017-03-08 中国药科大学 一种奥沙利铂热敏长循环脂质体的蔗糖溶液制剂及其制备方法
CA3050686A1 (en) * 2017-01-18 2018-07-26 Temasek Life Sciences Laboratory Limited Hyperstabilized liposomes increase targeting of mitotic cells
RS63953B1 (sr) 2017-03-15 2023-02-28 Modernatx Inc Jedinjenje i kompozicije za intracelularnu isporuku terapeutskih sredstava
JP7332478B2 (ja) 2017-03-15 2023-08-23 モデルナティエックス インコーポレイテッド 脂質ナノ粒子製剤
WO2018170322A1 (en) 2017-03-15 2018-09-20 Modernatx, Inc. Crystal forms of amino lipids
CN110662532A (zh) 2017-04-03 2020-01-07 加利福尼亚大学董事会 用于跨血脑屏障、透粘膜和经皮药物递送的可变形的纳米级媒介物(dnvs)
EP3638678B1 (en) 2017-06-14 2025-12-03 ModernaTX, Inc. Compounds and compositions for intracellular delivery of agents
MA49421A (fr) 2017-06-15 2020-04-22 Modernatx Inc Formulations d'arn
US10925831B2 (en) * 2017-08-28 2021-02-23 Wake Forest University Liposomal formulations of platinum-acridine anticancer agents and methods thereof
MX2020002348A (es) 2017-08-31 2020-10-08 Modernatx Inc Métodos de elaboración de nanopartículas lipídicas.
US11110060B2 (en) * 2017-10-25 2021-09-07 Arizona Board Of Regents On Behalf Of The University Of Arizona Compositions and methods for delivering pharmaceutical agents
US10606661B2 (en) * 2017-12-15 2020-03-31 Rubrik, Inc. On-demand provisioning of customized developer environments
EP3731846A4 (en) 2017-12-29 2022-03-02 Wayne State University DRUG DELIVERY SYSTEMS FOR THE TREATMENT OF INFECTION
FI3811949T3 (fi) 2018-06-20 2024-09-13 Fujifilm Corp Liposomikoostumukseen kapseloitua gemsitabiinia ja immuunitarkistuspistesalpaajaa käsittävä yhdistelmälääke
US12151029B2 (en) 2018-09-19 2024-11-26 Modernatx, Inc. PEG lipids and uses thereof
CN112996854B (zh) 2018-09-19 2024-08-30 摩登纳特斯有限公司 高纯度peg脂质和其用途
EP3853202A1 (en) 2018-09-19 2021-07-28 ModernaTX, Inc. Compounds and compositions for intracellular delivery of therapeutic agents
US12090235B2 (en) 2018-09-20 2024-09-17 Modernatx, Inc. Preparation of lipid nanoparticles and methods of administration thereof
WO2020115171A1 (en) * 2018-12-06 2020-06-11 Glaxosmithkline Biologicals Sa Immunogenic compositions
RU2706427C1 (ru) * 2018-12-27 2019-11-19 Федеральное государственное автономное образовательное учреждение высшего образования "Национальный исследовательский технологический университет "МИСиС" Способ лечения онкологических заболеваний с помощью инъекций лекарственного препарата
CN113939282A (zh) 2019-01-31 2022-01-14 摩登纳特斯有限公司 制备脂质纳米颗粒的方法
MX2021013842A (es) * 2019-05-14 2022-01-18 Pharmosa Biopharm Inc Composicion farmaceutica de un farmaco de acido debil y metodos de administracion.
JP7253735B2 (ja) 2019-07-02 2023-04-07 パナソニックＩｐマネジメント株式会社 通過可否判定装置、通過管理システム、通過可否判定方法、及び、コンピュータプログラム
AU2020351220A1 (en) 2019-09-19 2022-04-07 Modernatx, Inc. Carbonate containing lipid compounds and compositions for intracellular delivery of therapeutic agents
WO2021053163A1 (en) 2019-09-19 2021-03-25 Danmarks Tekniske Universitet Immune stimulating micelle composition
EP4031524A1 (en) 2019-09-19 2022-07-27 ModernaTX, Inc. Branched tail lipid compounds and compositions for intracellular delivery of therapeutic agents
US20220364139A1 (en) * 2019-09-24 2022-11-17 Pataigin, Llc Methods for determining growth and response
CN110571005B (zh) * 2019-09-27 2021-01-01 广西科技大学 一种固定化金属离子-磁性脂质体及其制备方法和应用
IL300676A (en) * 2020-08-20 2023-04-01 Bionanosim Bns Ltd A lipid system for the administration of OCA
KR102560135B1 (ko) 2020-12-04 2023-07-27 가톨릭대학교 산학협력단 표적 치료제의 효과적인 전달을 위한 다기능성 리포좀 조성물
EP4291898A1 (en) 2021-02-12 2023-12-20 Institut National de la Santé et de la Recherche Médicale (INSERM) Method for prognosis and treating a patient suffering from cancer
US11524023B2 (en) 2021-02-19 2022-12-13 Modernatx, Inc. Lipid nanoparticle compositions and methods of formulating the same
AU2021433065A1 (en) 2021-03-08 2023-09-28 Eyegene Inc. Vaccine composition for preventing sars-cov-2
US20240108545A1 (en) 2022-10-03 2024-04-04 West Pharmaceutical Services, Inc. Methods and adapters for mixing pharmaceutical complexes

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5023087A (en) * 1986-02-10 1991-06-11 Liposome Technology, Inc. Efficient method for preparation of prolonged release liposome-based drug delivery system
WO1997038010A2 (en) 1996-04-11 1997-10-16 The University Of British Columbia Fusogenic liposomes
US6897196B1 (en) 2001-02-07 2005-05-24 The Regents Of The University Of California pH sensitive lipids based on ortho ester linkers, composition and method
US7273620B1 (en) 2002-05-20 2007-09-25 University Of British Columbia Triggered release of liposomal drugs following mixing of cationic and anionic liposomes
US7149468B2 (en) 2002-07-25 2006-12-12 The Mcgraw-Hill Companies, Inc. Methods for improving certainty of test-taker performance determinations for assessments with open-ended items
AU2002350719A1 (en) * 2002-11-29 2004-06-23 Janssen Pharmaceutica N.V. Pharmaceutical compositions comprising a basic respectively acidic drug compound, a surfactant and a physiologically tolerable water-soluble acid respectively base
EP1663153A4 (en) 2003-05-20 2011-01-05 Aronex Pharmaceuticals Inc COMBINATION SCHEMOTHERAPY WITH A LIPOSOMAL PLATINUM COMPLEX
US20070248541A1 (en) * 2003-12-01 2007-10-25 Mitsubishi Pharma Corporation Liposome
TWI262798B (en) 2003-12-31 2006-10-01 Ind Tech Res Inst Liposome and drug deliver system
US20110020434A1 (en) 2005-09-02 2011-01-27 O'halloran Thomas V Nanoparticle arsenic-platinum compositions
WO2007049279A2 (en) * 2005-10-26 2007-05-03 Yissum Research Development Company Of The Hebrew University Of Jerusalem A liposomal combination and uses thereof

Also Published As

Publication number Publication date
RU2640934C2 (ru) 2018-01-12
JP2019123753A (ja) 2019-07-25
JP2017101085A (ja) 2017-06-08
US10213385B2 (en) 2019-02-26
JP6549172B2 (ja) 2019-07-24
CN104023793B (zh) 2017-11-24
KR20140097215A (ko) 2014-08-06
US20190175505A1 (en) 2019-06-13
JP2014532665A (ja) 2014-12-08
ES2694154T3 (es) 2018-12-18
IL232344A0 (en) 2014-06-30
WO2013066903A1 (en) 2013-05-10
US20160338958A1 (en) 2016-11-24
JP2019023243A (ja) 2019-02-14
RU2014120216A (ru) 2015-12-10
US20180015039A1 (en) 2018-01-18
US9717686B2 (en) 2017-08-01
CA2852564A1 (en) 2013-05-10
IL258740B (en) 2019-01-14
IL232344B (en) 2018-05-31
CN104023793A (zh) 2014-09-03
US9370489B2 (en) 2016-06-21
US20130115273A1 (en) 2013-05-09
EP2773426B1 (en) 2018-08-22
EP3424564A1 (en) 2019-01-09
MX360391B (es) 2018-10-31
IL258740A (en) 2018-06-28
EP2773426A1 (en) 2014-09-10
JP6143767B2 (ja) 2017-06-07
MX2014004960A (es) 2014-06-05

Similar Documents

Publication Publication Date Title
MX2014004960A (es) Composiciones liposomales combinadas para terapia contra el cancer.
BR112012009376A2 (pt) composição farmacêutica, forma de dosagem farmacêutica, processo para a sua preparação, métodos de tratamento e seu uso
BR112015000578A2 (pt) moduladores da via do complemento e usos dos mesmos
BR112014011841A2 (pt) material de entrega de fármacos hidrofóbicos, método para a produção do mesmo e métodos para a entrega de uma composição de entrega de fármacos
BR112016027705A2 (pt) lipídios biodegradáveis para distribuição de ácidos nucleicos
IN2014CN03465A (enExample)
BR112013022789A2 (pt) composições farmacêuticas que compreendem metformina e um inibidor dpp-4 ou um inibidor sglt-2
EA201692506A3 (ru) Ингибиторы репликации вирусов гриппа
UA103915C2 (ru) Твердая лекарственная форма, которая содержит линаглиптин и ингибитор sglt2, и ее применение
MX347734B (es) Anticuerpos anti-s100a4 y usos aplicaciones terapéuticas.
BR112014018953A8 (pt) Derivados de lupano triterpenoide e uso farmacêutico dos mesmos
BR112015021470A2 (pt) conjugado de polímero para administração de um agente bioativo
DOP2014000059A (es) Derivados de estra–1,3,5(10),16–tetraen–3–carboxamida, procedimientos para su preparación, preparados farmacéuticos que los contienen, así como su uso para la preparación de medicamentos
BR112015011430A2 (pt) composição para liberação imediata e prolongada
BR112015010779A2 (pt) moduladores de di-hidropirazol gpr40
BR112015010791A2 (pt) moduladores de gpr40 de di-hidropirazol
CL2015000289A1 (es) Compuesto citostatico derivado de niclosamida y compuesto alquilante derivado de 2,3,4,6,8-pentazabiciclo[4.3.0]nona-2,7-trieno; composicion farmaceutica que los comprende; y metodo para determinar si el tratamiento para un paciente con un tumor solido es adecuado.
BR112015008297A2 (pt) antagonistas de mglu2/3 para o tratamento de distúrbios autistas
BR112014010376A2 (pt) medicamento para o tratamento de doença do olho anterior que compreende rebamipida e um agente de retenção de lágrima
UY34899A (es) Derivados de estra-1,3,5(10), 16-tetraeno 3-sustituidos, procedimientos para su preparación, preparaciones farmacéuticas que los contienen, asi como su uso para la preparación de medicamentos
CL2010001174A1 (es) Uso de espironolactona, sus polimorfos, hidratos o solvatos para preparar un medicamento util para prevenir y/o tratar la esclerosis muiltiple.
MX2017013636A (es) Combinacion de dosis fija resistente a la manipulacion que proporciona una liberacion rapida de dos farmacos desde diferentes particulas.
BR112014013878A2 (pt) emplastro
UY33723A (es) ?COMPUESTOS Y SU USO PARA TRATAMIENTO DE ENFERMEDADES RELACIONADAS CON Aß?.
BR112012020377A8 (pt) utilização de um ou mais selecionado do grupo constituído por um composto da fórmula (i), uma mistura racêmica-diastereomérica e um isômero óptico do referido composto, e um sal farmaceuticamente aceitável e uma pródroga do mesmo, método, composição farmacêutica e kit para tratamento de caquexia e embalagem comercial

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL